16,106 Shares in ADMA Biologics Inc (NASDAQ:ADMA) Acquired by Allianz Asset Management GmbH

Key Points

• Allianz Asset Management GmbH acquired 16,106 shares of ADMA Biologics Inc valued at approximately $320,000 in the first quarter.
• Several institutional investors have increased their stakes in ADMA Biologics, with B Group Inc's position valued at approximately $39.2 million, substantially impacting the overall ownership of institutional investors at 75.68%.
• Despite a reported revenue increase of 40.2% year-over-year, ADMA Biologics missed earnings per share estimates, reporting $0.14 per share against the expected $0.16.

Allianz Asset Management GmbH acquired a new position in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 16,106 shares of the biotechnology company's stock, valued at approximately $320,000.

A number of other institutional investors have also added to or reduced their stakes in the company. Tsfg LLC bought a new position in shares of ADMA Biologics during the first quarter valued at $51,000. Farther Finance Advisors LLC lifted its stake in ADMA Biologics by 1,149.1% in the first quarter. Farther Finance Advisors LLC now owns 2,723 shares of the biotechnology company's stock worth $53,000 after purchasing an additional 2,505 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in ADMA Biologics in the 4th quarter worth $85,000. CIBC Private Wealth Group LLC increased its position in shares of ADMA Biologics by 137.1% during the fourth quarter. CIBC Private Wealth Group LLC now owns 5,108 shares of the biotechnology company's stock valued at $95,000 after buying an additional 2,954 shares during the period. Finally, Covestor Ltd boosted its stake in ADMA Biologics by 7,038.1% during the fourth quarter. Covestor Ltd now owns 5,996 shares of the biotechnology company's stock worth $103,000 after acquiring an additional 5,912 shares in the last quarter. 75.68% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ADMA has been the subject of a number of analyst reports. Wall Street Zen cut shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th. Raymond James Financial boosted their price objective on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research report on Thursday, May 8th.

ADMA Biologics Stock Down 9.0%

NASDAQ ADMA traded down $1.68 during trading on Thursday, reaching $16.86. 9,792,365 shares of the company's stock traded hands, compared to its average volume of 3,118,274. The company's 50 day simple moving average is $18.76 and its two-hundred day simple moving average is $18.81. The company has a debt-to-equity ratio of 0.22, a current ratio of 6.58 and a quick ratio of 3.36. ADMA Biologics Inc has a 12-month low of $11.55 and a 12-month high of $25.67. The firm has a market cap of $4.03 billion, a price-to-earnings ratio of 19.84 and a beta of 0.38.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.02). ADMA Biologics had a return on equity of 47.16% and a net margin of 45.01%. The company had revenue of $114.80 million during the quarter, compared to analysts' expectations of $116.40 million. During the same period in the previous year, the firm posted $0.08 EPS. ADMA Biologics's revenue was up 40.2% compared to the same quarter last year. As a group, sell-side analysts forecast that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

Insider Activity at ADMA Biologics

In related news, Director Jerrold B. Grossman sold 10,000 shares of the stock in a transaction on Monday, June 9th. The stock was sold at an average price of $21.31, for a total transaction of $213,100.00. Following the completion of the sale, the director directly owned 478,194 shares of the company's stock, valued at $10,190,314.14. This trade represents a 2.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Steve Elms sold 194,749 shares of the firm's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $20.24, for a total transaction of $3,941,719.76. Following the transaction, the director owned 87,330 shares of the company's stock, valued at $1,767,559.20. This trade represents a 69.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 464,621 shares of company stock valued at $9,644,269 over the last 90 days. 3.50% of the stock is owned by corporate insiders.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.